

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Decision Cover Letter

### Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-101786-PIP01-25

### Scope of the Application

#### Active Substance(s)

(R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide

#### Condition(s)

Treatment of PIK3CA-related disorders with vascular malformations and/or overgrowth spectrum

#### Pharmaceutical Form(s)

Capsule, hard

#### Route(s) of Administration

ORAL USE

#### Name / Corporate name of the PIP applicant

Relay Therapeutics, Inc.

#### Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Relay Therapeutics, Inc. submitted to the licensing authority on 14/02/2025 19:29 GMT an application for a Paediatric Investigation Plan

The procedure started on 05/03/2025 23:02 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-101786-PIP01-25

Of 10/03/2026 07:48 GMT

On the adopted decision for (R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (MHRA-101786-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for (R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide, Capsule, hard , ORAL USE .

This decision is addressed to Relay Therapeutics, Inc., 60 Hampshire Street, Cambridge, UNITED STATES OF AMERICA, 02139

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of PIK3CA-related disorders with vascular malformations and/or overgrowth spectrum  
The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age  
Pharmaceutical form(s): Capsule, hard  
Route(s) of administration: ORAL USE  
Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of PIK3CA-related disorders with vascular malformations and/or overgrowth spectrum

## 2.2 Indication(s) targeted by the PIP:

Treatment of PIK3CA-related disorders with vascular malformations and/or overgrowth spectrum in paediatric patients from 2 years to less than 18 years of age

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Capsule, hard

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of additional strength(s) of an oral solid dosage form appropriate to the paediatric population.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 (RLY-2608-201) Three-part, randomised, double-blind study to evaluate efficacy and safety of RLY-2608 compared to placebo in children from 2 years to less than 18 years of age (and adults) with PIK3CA-related overgrowth spectrum (PROS) and vascular malformations driven by PIK3CA mutations.
Extrapolation, Modeling & Simulation Studies	3	Study 3 Population pharmacokinetic analyses to support RLY-2608 dose selection for children from 2 years to less than 18 years of age. Study 4 Exposure-response analyses to support extrapolation of efficacy from the adults and older children to those from 2 years to less than 6 years of age. Extrapolation Plan Studies 2 (RLY-2608-201), 3 and 4 are part of an extrapolation plan of efficacy from adult and paediatric participants from 6 years to less than 18 years of age, to the paediatric

		population from 2 years to less than 6 years of age.
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/12/2033
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	No